GlassScriptPhysician profile
Annie K Thomas
NPI 1801892138
$7,966.89
in general payments reported to CMS, 2019-2025
32 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,643 · 2020: $1,360 · 2021: $735 · 2022: $909 · 2023: $1,199 · 2024: $802 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,008.20 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $825.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $688.17 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $681.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $651.88 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $474.48 | 2019-2025 | Unithroid |
| Amgen INC. | $432.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Radius Health, INC. | $432.22 | 2019-2025 | Tymlos |
| Ibsa Pharma INC. | $419.55 | 2019-2023 | Tirosint, Licart |
| Abbvie INC. | $260.52 | 2019-2025 | Synthroid |
| Insulet Corporation | $250.43 | 2019-2025 | Omnipod |
| Medtronic, INC. | $244.80 | 2022-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Amarin Pharma, INC. | $215.12 | 2019-2020 | |
| Dexcom, INC. | $202.30 | 2019-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $193.05 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $167.76 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $149.62 | 2025 | Cequr Simplicity |
| Beta Bionics, INC. | $119.76 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbott Laboratories | $99.31 | 2019-2023 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $63.12 | 2025 | Rezdiffra |
| Medtronic Minimed, INC. | $53.97 | 2019-2020 | |
| Shire North American Group INC | $53.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.65 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.65 | 2022-2023 | Cycloset |
| Ethicon US, LLC | $30.97 | 2023 | N/A |
| Ascendis Pharma Endocrinology INC | $28.88 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $20.54 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $20.41 | 2025 | Gvoke Hypopen |
| Mannkind Corporation | $20.30 | 2019 | |
| Corcept Therapeutics | $17.72 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $15.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.